1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
1
Active Trials
200 recruiting
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Apollomics, Inc. is a company with 1 orphan drug designation across 4 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| brain neoplasm | - | Des.TrialAppr. |
| lung cancer | vebreltinib | Des.TrialAppr. |
| non-small cell lung carcinoma | vebreltinib | Des.TrialAppr. |
| non-small cell squamous lung carcinoma | vebreltinib | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
18
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
18
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio